Journey Advisory Group LLC Cuts Holdings in Eli Lilly and Company $LLY

Key Points

• Journey Advisory Group LLC reduced its stake in Eli Lilly by 2.4%, now holding 22,918 shares valued at approximately $17.87 million, making it their 14th largest position.
• In the first quarter, several other institutional investors increased their stakes significantly, with WestEnd Advisors boosting by 210% and Citizens National Bank Trust Department by 180%.
• Eli Lilly reported a strong quarterly performance with a 37.6% increase in revenue year-over-year, achieving earnings per share of $6.31, surpassing analysts' expectations of $5.59.

Journey Advisory Group LLC cut its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 2.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 22,918 shares of the company's stock after selling 556 shares during the quarter. Eli Lilly and Company makes up about 1.4% of Journey Advisory Group LLC's holdings, making the stock its 14th biggest position. Journey Advisory Group LLC's holdings in Eli Lilly and Company were worth $17,865,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. WestEnd Advisors LLC boosted its stake in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after acquiring an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company in the first quarter valued at about $27,000. Citizens National Bank Trust Department boosted its stake in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after acquiring an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. purchased a new position in Eli Lilly and Company in the first quarter valued at about $40,000. Finally, TD Capital Management LLC raised its position in shares of Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company's stock valued at $46,000 after purchasing an additional 31 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Eli Lilly and Company

In related news, EVP Daniel Skovronsky purchased 1,000 shares of the firm's stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $634.40 per share, with a total value of $634,400.00. Following the acquisition, the executive vice president directly owned 137,660 shares of the company's stock, valued at approximately $87,331,504. This represents a 0.73% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jamere Jackson purchased 200 shares of the firm's stock in a transaction dated Friday, August 8th. The stock was bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the acquisition, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 4,514 shares of company stock worth $2,894,841. Company insiders own 0.14% of the company's stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Weiss Ratings reissued a "hold (c+)" rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. HSBC boosted their price target on shares of Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target on the stock. in a research report on Sunday, August 17th. The Goldman Sachs Group boosted their price target on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the company a "buy" rating in a research report on Friday, October 10th. Finally, UBS Group lowered their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $939.12.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $803.53 on Monday. The firm's 50 day simple moving average is $753.09 and its 200 day simple moving average is $765.70. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The firm has a market capitalization of $760.51 billion, a PE ratio of 52.52, a price-to-earnings-growth ratio of 1.15 and a beta of 0.47. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $935.63.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business's revenue for the quarter was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.